CTLA4 and melanoma: There is a new era with the introduction of immunotherapy: CTLA‐4 antibody targeting agents and PD‐1 and PDL‐1 inhibitors have been shown to be effective in the treatment of metastasized melanoma, including in patients with brain metastases from melanoma (MDM) [10].